Drug intelligence / Profile preview

MT302

Development stage: Preclinical
Lead developer: Myeloid Therapeutics
Administration: Intravenous

Overview

**MT302** is a preclinical Mthera Pharma drug candidate for **cancer cachexia**. Mthera Pharma lists the asset as **NB-02** and describes it as developed using its proprietary **MCMT multi-component multi-target platform**. The specific active constituents, modality, molecular targets, route of administration, and mechanism of action have not been publicly disclosed.

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on MT302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT302.

Explore the full profile